Porownywarka
Pasireotide vs Octreotide side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Pasireotide | Octreotide |
|---|---|---|
| Kategoria | Hormonalne | Hormonalne |
| Znany tez jako | Signifor, Signifor LAR | Sandostatin, Octreotide LAR, Sandostatin LAR, Mycapssa |
| Zatwierdzony przez FDA | Tak | Tak |
| Status kliniczny | FDA approved for Cushing's disease and acromegaly
| FDA Approved - Multiple indications
|
| Czego oczekiwac | Cushing's disease, acromegaly, hormone disorders | Acromegaly, carcinoid tumors, hormone regulation |
| Jak dziala | Pasireotide is reported to act across four somatostatin receptor subtypes: SSTR1, SSTR2, SSTR3, and SSTR5. The source emphasizes SSTR5 affinity, which is relevant to corticotroph tumors in Cushing's disease and ACTH suppression. For acromegaly, the described receptor targets include SSTR2 and SSTR5 on tumors that secrete growth hormone. The same receptor activity in pancreatic and gastrointestinal tissues is presented as a contributor to reduced insulin, GLP-1, and GIP signaling, which may explain the high rate of hyperglycemia reported in trials. | Octreotide is presented as a synthetic analog of somatostatin. The evidence describes preferential binding at SSTR2 and SSTR5, followed by intracellular signaling changes involving adenylate cyclase and calcium channels. Those receptor effects are associated with lower secretion of growth hormone, glucagon, insulin, gastrin, and other gut hormones. In the supplied acromegaly context, reduced growth hormone output is linked with lower IGF-1; in carcinoid-related symptoms, the source also connects activity to slower gut motility and reduced splanchnic blood flow. |
| Typowe dawkowanie | 300-900 mcg twice daily · Twice daily (SC) or monthly (LAR) | 100-500 mcg SC 2-3x daily or LAR monthly · 2-3x daily (SC) or monthly (LAR) · Subcutaneous or intramuscular depot |
| Dawkowanie z badań | 600-900 mcg SC twice daily · Long-term / chronic use · Subcutaneous or intramuscular | 50-200 mcg SC 3x daily (immediate) · Long-term / chronic use · Subcutaneous or intramuscular depot |
| Typowy czas trwania | Long-term / chronic use | Long-term / chronic use |
| Podanie | Subcutaneous or intramuscular | Subcutaneous injection, intramuscular depot, or oral capsule formulations are reported. |
| Timing | Morning or as directed With or without food | Morning or as directed With or without food |
| Poziom dowodów | Zatwierdzone przez FDA | Zatwierdzone przez FDA |
| Mozliwe skutki uboczne |
+4 więcej
|
+5 więcej
|
| Podsumowanie researchu | The source describes randomized clinical evidence in Cushing's disease and acromegaly. In the 12-month Cushing's disease phase 3 study, 162 participants were randomized and urinary free cortisol normalization was reported in about 15% to 26% depending on dose, along with broader cortisol reductions and symptom measures. In acromegaly, the PAOLA phase 3 trial is described as showing biochemical control in roughly 15% to 20% of patients receiving pasireotide LAR after inadequate response to octreotide or lanreotide, compared with 0% in those continuing older analog therapy. Across these trial summaries, hyperglycemia is a repeated safety concern, with glucose-lowering medication sometimes needed. | The supplied evidence characterizes Octreotide as a well-studied peptide drug with human clinical use rather than only laboratory-stage data. It describes long-acting depot use in acromegaly and cites the CHIASMA OPTIMAL phase 3 trial, where oral octreotide maintained biochemical control in about 58% of previously injection-responsive acromegaly patients compared with 19% on placebo over 9 months. The source also reports use in neuroendocrine tumors and carcinoid syndrome, with safety considerations including gallstones, gastrointestinal effects, and altered blood sugar. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.